Search
Nilotinib
go.drugbank.com/drugs/DB04868ApprovedInvestigational), another tyrosine kinase inhibitor used as a first-line treatment for CML. … A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to treatment with imatinib (Gleevec
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexProducts: TASIGNA® 150 MG CAPSULAS, TASIGNA (200 MG)Fosinopril
go.drugbank.com/drugs/DB00492ApprovedInvestigationalFosinopril may be used to treat mild to moderate hypertension, as an adjunct in the treatment of congestive heart failure, and to slow the rate of progression of renal disease in hypertensive individuals … ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS).
Mixtures: MONOPRIL PLUS 10 MG/12.5 MG TABLET, 28 ADET, MONOPRIL PLUS 20 MG/12.5 MG TABLET, 28 ADETCategories: Agents Acting on the Renin-Angiotensin SystemOlaparib
go.drugbank.com/drugs/DB09074ApprovedInvestigational[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell … [L41100, L40908, L43792] It was first approved by the FDA and EU in December 2014,[A246020] and by Health Canada in April 2016.[L42820]
Categories: MATE 2-K Inhibitors, P-glycoprotein substrates with a Narrow Therapeutic IndexSynonyms: 4-(3-{[4-(cyclopropylcarbonyl)piperazin-1-yl]carbonyl}-4-fluorobenzyl)phthalazin-1(2H)-oneTALL-104
go.drugbank.com/drugs/DB17360InvestigationalSynonyms: Human major histocompatibility complex (MHC) non-restricted T-cell line 104DCP-001
go.drugbank.com/drugs/DB17423InvestigationalSynonyms: Proliferation arrested myelomonocytic leukemic cell line-derived cells with a mature dendritic cell phenotypeEthambutol
go.drugbank.com/drugs/DB00330ApprovedInvestigational[A229048] Ethambutol was granted FDA approval on 6 November 1967.[L31663] … [L31743] Ethambutol was first described in the literature in 1961.[A229048] It was developed out of a need for therapies active against isoniazid resistant strains of _Mycobacterium tuberculosis_.
Mixtures: RIFAMPICIN 150 MG/ISONIAZID 75 MG/PYRAZINAMIDE 400 MG/ETHAMBUTOL 275 MG, RIFAMPICIN 150 MG/ISONIAZID 75 MG/PYRAZINAMIDE 400 MG/ETHAMBUTOL 275 MGCategories: MATE 1 Substrates, MATE 2 SubstratesCarbidopa
go.drugbank.com/drugs/DB00190ApprovedInvestigationalCarbidopa presents a chemical denomination of N-amino-alpha-methyl-3-hydroxy-L-tyrosine monohydrate. … therapy developed by Mayne Pharma in 1992.
Mixtures: DUODOPA 20 MG/ML + 5 MG/ML INTESTINAL JEL, 7 ADET, Zuades 5 mg/1,25 mg Tabletten zur Herstellung einer Suspension zum Einnehmen für ein DosiergerätCategories: Aromatic L-amino Acid Decarboxylase InhibitorsBrigatinib
go.drugbank.com/drugs/DB12267ApprovedInvestigational[A31311] It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the EML4-ALK fusion gene, which is a pivotal player in the transformation of susceptible lung parenchyma. … [A31313] Brigatinib was developed by Ariad Pharmaceuticals, a subsidiary of Takeda Pharmaceutical Company Limited, and FDA-approved on April 28, 2017.[L1026]
Mixtures: ALUNBRİG 90 MG VE 180 MG FİLM KAPLI TABLET TEDAVİYE BAŞLANGIÇ PAKETİ, 7 ADET 90 MG VE 21 ADET 180 MG, ALUNBRİG 90 MG VE 180 MG FİLM KAPLI TABLET TEDAVİYE BAŞLANGIÇ PAKETİ, 7 ADET 90 MG VE 21 ADET 180 MGCategories: Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index, MATE 1 InhibitorsEliglustat
go.drugbank.com/drugs/DB09039ApprovedInvestigational[L41404,A7634] Eliglustat was approved by the FDA in August 2014 as an oral substrate reduction therapy for the first-line treatment of type 1 Gaucher disease. … [A3752,L41404] Gaucher disease is a rare genetic disorder characterized by the deficiency of acid β-glucosidase, an enzyme that converts glucosylceramide into glucose and ceramide.
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesSynonyms: N-[(1R,2R)-1-(2,3-Dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-(1-pyrrolidinyl)-2-propanyl]octanamideHexetidine
go.drugbank.com/drugs/DB08958ApprovedWithdrawnA bactericidal and fungicidal antiseptic. It is used as a 0.1% mouthwash for local infections and oral hygiene.
Mixtures: Isozid - H farblos - alkoholische Lösung zur Hautdesinfektion, Isozid - H gefärbt - alkoholische Lösung zur HautdesinfektionCategories: Heterocyclic Compounds, 1-Ring